265 related articles for article (PubMed ID: 30365983)
1. Role of HSD17B13 in the liver physiology and pathophysiology.
Su W; Mao Z; Liu Y; Zhang X; Zhang W; Gustafsson JA; Guan Y
Mol Cell Endocrinol; 2019 Jun; 489():119-125. PubMed ID: 30365983
[TBL] [Abstract][Full Text] [Related]
2. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease.
Wang MX; Peng ZG
Pharmacol Ther; 2023 Jun; 246():108428. PubMed ID: 37116587
[TBL] [Abstract][Full Text] [Related]
3. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.
Zhang X; Wang Y; Liu P
Protein Cell; 2017 Jan; 8(1):4-13. PubMed ID: 27757845
[TBL] [Abstract][Full Text] [Related]
4. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
5. Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity.
Ma Y; Karki S; Brown PM; Lin DD; Podszun MC; Zhou W; Belyaeva OV; Kedishvili NY; Rotman Y
J Lipid Res; 2020 Nov; 61(11):1400-1409. PubMed ID: 32973038
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.
Su W; Wang Y; Jia X; Wu W; Li L; Tian X; Li S; Wang C; Xu H; Cao J; Han Q; Xu S; Chen Y; Zhong Y; Zhang X; Liu P; Gustafsson JÅ; Guan Y
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11437-42. PubMed ID: 25028495
[TBL] [Abstract][Full Text] [Related]
7. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
[TBL] [Abstract][Full Text] [Related]
8. 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
Ma Y; Brown PM; Lin DD; Ma J; Feng D; Belyaeva OV; Podszun MC; Roszik J; Allen JN; Umarova R; Kleiner DE; Kedishvili NY; Gavrilova O; Gao B; Rotman Y
Hepatology; 2021 May; 73(5):1701-1716. PubMed ID: 32779242
[TBL] [Abstract][Full Text] [Related]
9. Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice.
Adam M; Heikelä H; Sobolewski C; Portius D; Mäki-Jouppila J; Mehmood A; Adhikari P; Esposito I; Elo LL; Zhang FP; Ruohonen ST; Strauss L; Foti M; Poutanen M
FASEB J; 2018 Jun; 32(6):3434-3447. PubMed ID: 29401633
[TBL] [Abstract][Full Text] [Related]
10. HSD17B13: A Potential Therapeutic Target for NAFLD.
Zhang HB; Su W; Xu H; Zhang XY; Guan YF
Front Mol Biosci; 2021; 8():824776. PubMed ID: 35071330
[TBL] [Abstract][Full Text] [Related]
11. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
12. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13.
Liu S; Sommese RF; Nedoma NL; Stevens LM; Dutra JK; Zhang L; Edmonds DJ; Wang Y; Garnsey M; Clasquin MF
Nat Commun; 2023 Aug; 14(1):5158. PubMed ID: 37620305
[TBL] [Abstract][Full Text] [Related]
14. Expression and localization of HSD17B13 along mouse urinary tract.
Zhang H; Chang J; Dai Z; Wang Q; Qiao R; Huang Y; Ma B; Jiang J; Zhu C; Su W; Zhang X; Guan Y
Am J Physiol Renal Physiol; 2024 May; ():. PubMed ID: 38779753
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
[TBL] [Abstract][Full Text] [Related]
16. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.
Amangurbanova M; Huang DQ; Loomba R
Aliment Pharmacol Ther; 2023 Jan; 57(1):37-51. PubMed ID: 36349732
[TBL] [Abstract][Full Text] [Related]
17. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
[TBL] [Abstract][Full Text] [Related]
18. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
Wang M; Li J; Li H; Dong B; Jiang J; Liu N; Tan J; Wang X; Lei L; Li H; Sun H; Tang M; Wang H; Yan H; Li Y; Jiang J; Peng Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628360
[TBL] [Abstract][Full Text] [Related]
19. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma.
Chen J; Zhuo JY; Yang F; Liu ZK; Zhou L; Xie HY; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):220-226. PubMed ID: 29748147
[TBL] [Abstract][Full Text] [Related]
20. BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes.
Alcober-Boquet L; Kraus N; Huber LS; Vutukuri R; Fuhrmann DC; Stross C; Schaefer L; Scholich K; Zeuzem S; Piiper A; Schulz MH; Trebicka J; Welsch C; Ortiz C
Am J Physiol Cell Physiol; 2024 Mar; 326(3):C880-C892. PubMed ID: 38223924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
